- Home
- APVO vs NBY Comparison
APVO vs NBY Comparison
Compare APVO & NBY Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- APVO
- NBY
- Stock Information
- Founded
- APVO 2016
- NBY 2000
- Country
- APVO United States
- NBY United States
- Employees
- APVO N/A
- NBY N/A
- Industry
- APVO Biotechnology: Pharmaceutical Preparations
- NBY
- Sector
- APVO Health Care
- NBY
- Exchange
- APVO Nasdaq
- NBY Nasdaq
- Market Cap
- APVO 4.1M
- NBY 3.4M
- IPO Year
- APVO N/A
- NBY 2007
- Fundamental
- Price
- APVO $0.32
- NBY $0.59
- Analyst Decision
- APVO Strong Buy
- NBY Strong Buy
- Analyst Count
- APVO 1
- NBY 1
- Target Price
- APVO $296.00
- NBY $0.85
- AVG Volume (30 Days)
- APVO 3.7M
- NBY 51.3K
- Earning Date
- APVO 05-14-2025
- NBY 05-27-2025
- Dividend Yield
- APVO N/A
- NBY N/A
- EPS Growth
- APVO N/A
- NBY N/A
- EPS
- APVO N/A
- NBY 0.57
- Revenue
- APVO N/A
- NBY $9,781,000.00
- Revenue This Year
- APVO N/A
- NBY $23.91
- Revenue Next Year
- APVO N/A
- NBY $32.05
- P/E Ratio
- APVO N/A
- NBY $1.27
- Revenue Growth
- APVO N/A
- NBY N/A
- 52 Week Low
- APVO $0.35
- NBY $0.36
- 52 Week High
- APVO $38.48
- NBY $9.10
- Technical
- Relative Strength Index (RSI)
- APVO 24.10
- NBY 53.07
- Support Level
- APVO $0.60
- NBY $0.55
- Resistance Level
- APVO $0.35
- NBY $0.62
- Average True Range (ATR)
- APVO 0.04
- NBY 0.04
- MACD
- APVO 0.05
- NBY 0.00
- Stochastic Oscillator
- APVO 3.06
- NBY 61.54
About APVO Aptevo Therapeutics Inc.
Aptevo Therapeutics Inc is a clinical-stage research and development biotechnology company focused on developing novel immunotherapeutic candidates for the treatment of different forms of cancer. Its clinical candidates are; ALG.APV-527, which targets co-stimulatory receptors and tumor antigens, and CD3xCD123, which is being developed as a potential treatment of frontline acute myelogenous leukemia. The company's preclinical candidates, APVO711, APVO0442, and APVO603, are being developed using the ADAPTIR modular protein technology platform. The company's versatile and robust ADAPTIR and ADAPTIR-FLEX platforms are designed to generate monospecific, bispecific, and multi-specific antibody candidates that are capable of enhancing the human immune system against cancer cells.
About NBY NovaBay Pharmaceuticals Inc.
NovaBay Pharmaceuticals Inc is a biopharmaceutical company that develops and sells scientifically-created and clinically-proven eyecare, wound care, and skin care products. Its product, Avenova Antimicrobial Lid and Lash Solution (Avenova Spray), is laboratory tested to have broad antimicrobial properties as it removes foreign material, including microorganisms and debris from the skin around the eye, including the eyelid. Avenova Spray is available directly to consumers through online distribution channels and is also often prescribed and dispensed by eyecare professionals for blepharitis and dry-eye disease.